NCT07045701Phase 2, phase 3Enrolling by invitation

FMXIN002 in Patients at Risk of Anaphylaxis

Study sponsor: Nasus Pharma

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-06-12Estimated
Enrollment · participants30Estimated
Source updated2025-07-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.